No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Q32 Bio Inc. is a clinical-stage biotechnology company, headquartered in Waltham, Massachusetts, focused on creating innovative biologic treatments. Operating within the United States, its primary objective is to re-establish a healthy immune balance in individuals suffering from autoimmune and inflammatory conditions stemming from pathological immune dysfunction. The company's primary therapeutic candidate, ADX-097, is a humanized monoclonal antibody fusion protein engineered to restore proper complement regulation. This compound has successfully concluded its Phase I clinical trial and is being advanced for the treatment of severe renal and other complement-mediated diseases that present significant unmet medical needs. These include specific conditions like lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. Furthermore, Q32 Bio is progressing Bempikibart (ADX-914), a fully human monoclonal antibody that functions as an interleukin-7 receptor alpha antagonist. By disrupting the signaling pathways mediated by interleukin-7 and thymic stromal lymphopoietin, Bempikibart aims to normalize adaptive immune function. This promising candidate is currently undergoing Phase II clinical trials for the management of atopic dermatitis and alopecia areata. The company, established in 2017, was previously known as AdMIRx Inc. and rebranded to Q32 Bio Inc. in April 2020.
www.q32bio.comNo one on the platform currently holds 0T6G.L.
No tracked institution reports a position in 0T6G.L as of their last filing.
No one on the platform has traded 0T6G.L yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 186.5% | — | — | — | ||
| Rev. Growth % | 81.9% | |||||
| Profit Margin % | 55.5% | |||||
| Free Cash Flow Margin % | -62.4% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $400000 | -80.0% | $-1.47 | $-1.47–$-1.47 | — | 1 |
| 2027 | $1M | +150.0% | $-1.89 | $-1.89–$-1.89 | — | 1 |
| 2028 | $3M | +150.0% | $-1.82 | $-1.82–$-1.82 | — | 1 |
| 2029 | $61M | +2342.0% | $-0.78 | $-0.78–$-0.78 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | $-0.46 | $-0.44 | +4.3% |
| 2026-05-05 | $-0.68 | $-0.54 | +20.6% |
| 2026-03-10 | $-0.86 | $4.58 | +632.6% |
| 2025-11-13 | $-1.19 | $-0.60 | +49.3% |
| 2025-08-06 | $-0.98 | $-0.78 | +20.5% |
| 2025-05-08 | $-1.23 | $-0.90 | +26.8% |
| 2025-03-11 | $-1.53 | $-1.16 | +23.9% |
| 2024-11-07 | $-1.38 |
| $-1.46 |
| -5.9% |
| $48M |
| — |
| 0IL8.LKyntra Bio, Inc. | $7.54 | -2.84% | $30M | — |
| 0JQ2.LKALA BIO, Inc. | $0.54 | +2.86% | $75194 | — |
Source: Financial Modeling Prep · peers by sector/industry